72 results about "Cefuroxime" patented technology

A compound anti-beta-lactamase antibiotic is prepared from cefuroxime or its salt, sulbactam or its salt, and tazobactan or its salt. Its advantages are broad spectrum and high antibacterial effect.

The invention discloses a method for preparing cefuroxime acid. The method comprises the following steps of: performing a chloride acylation reaction on 7-aminocephalosporanic acid (7-ACA) and methoxyiminofuran acetate serving as raw materials; performing deacetylation to synthesize DCCF; performing nucleophilic addition on the DCCF and chlorosulfonyl isocyanate (CSI) serving as a strong carbamoyl reagent to obtain chlorosulfonyl cefuroxime; and hydrolyzing the chlorosulfonyl cefuroxime to obtain cefuroxime acid. In the preparation method, the preparation process is simple, and the cefuroximeacid is crystallized by adopting aqueous solution, so that the loss of organic solvents is reduced; simultaneously, aids are added selectively in the reaction process to improve the quality of products, so that finished products with high purity and yield and good colors are obtained. The purity of the cefuroxime acid prepared by the method is more than 98.5 percent, and the weight yield is approximately 100 percent.

The invention relates to a method for preparing 3-descarbamoyl-cefuroxime acid. The method comprises the following steps of: (1) dissolving 7-aminocephalosporanic acid (7-ACA) in water or a methanol solution to prepare a 7-ACA solution, and performing hydrolysis reaction to obtain a 3-deacetyl-7-aminocephalosporanic acid (7-DACA) solution; (2) dissolving an acylchlorination reagent in a solvent, adding a cosolvent, adding (Z)-2-methoxyimino-2-(furyl-2-yl)acetic acid ammonium salt (SIMA), reacting, filtering, adding water or performing rotary evaporation to remove the excessive acylchlorination reagent, performing vacuum rotary evaporation, adding a homogenization reagent, and dissolving to obtain a (Z)-2-(furyl-2-yl)-2-(methoxyimino)-acetyl chloride (SMIF-Cl) solution; (3) adding the homogenization reagent into the 7-DACA solution, dripping the SMIF-Cl solution, regulating the pH value, preserving heat and reacting to obtain a reaction solution; and (4) decolorizing the reaction solution, regulating the pH value, adding purified water, growing a crystal, filtering, and performing vacuum drying. Reactants form a homogeneous system by adding the homogenization reagent, so that the contact area of the reactants is expanded, the reaction rate is increased, and reaction time is shortened.

The invention provides a novel compound of cefuroxime dibenzyl ethylenediamine salt and a preparation method as well as the method for the preparation of cefuroxime dibenzyl ethylenediamine salt or purification of cefuroxime or cefuroxime salt.

The invention provides a method for preparing cefuroxime acid. The method comprises the following steps: (1) selectively hydrolyzing 7-aminocephalosporanic acid (7-ACA) with aqueous alkali so as to obtain 3-deacetylation-7-aminocephalosporanic acid (7-DACA); (2) condensing 2-(2-furyl)-2-(methoxyimino)acetic acid-(2,5-dioxo-pyrrolidyl)-1-ester and 7-DACA so as to obtain 3-decarbamyl-cefuroxime acid (DCCF); and (3) modifying 3-hydroxymethyl of DCCF with chlorosulfonyl isocyanate so as to obtain the cefuroxime acid. In the method, low-temperature selective hydrolysis is carried out by using inorganic base to remove the 3-ester group of 7-ACA so as to prepare 7-DACA; C7-amino modification is carried out by an active ester method so as to obtain DCCF; and the 3-hydroxymethyl of DCCF is modified into carbamoyl methoxyl so as to obtain the cefuroxime acid. The method has the advantages of less emission of three wastes and high yield, is simple and convenient to operate, and is suitable for industrial production.

A compound powder injection or freeze-dried powder injection is prepared from the sodium (or potassium) salt of probenecid and the beta-lactam kind of antibiotics including penicillin G, ampicillin, ancef, cefuroxime, cefotaxime and cefoxitin. It can elongate the half life of antibiotic, increase the AUC and plasma level and prevent the generation of drug-resistant bacteria.

The invention provides a method for preparing cefuroxime acid. The method is characterized by comprising the following steps: (1) mixing deammonized formyl cefuroxime in liquid ester, adding a strong amino carbamylation reagent sulfonylisocynate, and performing a temperature-controlled reaction; (2) adding purified water after the reaction is completed, and performing hydrolysis; (3) adding the liquid ester after hydrolysis is completed, adjusting the pH value to be 1.9-2.0 by using hydrochloric acid, standing for layering, and performing vacuum concentration on an organic layer so as to obtain an organic layer concentrated solution; (4) adding purified water into the organic layer concentrated solution, performing crystallization, and filtering so as to obtain cefuroxime acid, wherein the liquid ester used in the step (1) and the step (3) is selected from methyl acetate, acetic ether, n-butyl acetate, methyl formate, ethyl formate and propyl formate. The method for preparing cefuroxime acid, which is provided by the invention, is green and environmental-friendly, low in cost, high in yield and good in quality.

The invention relates to cefuroxime lysine, and particularly relates to a cefuroxime lysine medicinal composition. The cefuroxime lysine medicinal composition comprises cefuroxime lysine and sodium chloride serving as active ingredients in a weight ratio of 10: (0.1-2), and at least one of mannitol, sorbitol, sodium bisulfite and sodium metabisulfite can be added to the active ingredients. The cefuroxime lysine medicinal composition has the advantages of low impurity content, good stability and high flowability and is very suitable for clinical application.

The invention provides a beta-lactam compound antibiotic composition, which contains cefuroxime and a tazobactam sodium monohydrate, or cefuroxime salts and the tazobactam sodium monohydrate, wherein the weight ratio of the cefuroxime salts counted according to the cefuroxime to the tazobactam sodium monohydrate counted according to the tazobactam is (1-8):1. The beta-lactam compound antibiotic composition disclosed by the invention is used for being prepared into a clinically-acceptable medicinal preparation with the cefuroxime and salts thereof as well as the tazobactam sodium monohydrate as active components. According to the beta-lactam compound antibiotic composition, the tazobactam sodium monohydrate is mixed with the cefuroxime and salts thereof so as to improve the flowability of composition powder, enable the uniformity of the medicament to be better in the production process and improve the yield of the product; and the beta-lactam compound antibiotic composition has saved production cost and is especially suitable for popularization and application.

The invention relates to a preparation method of an anti-form cefuroxime derivative. The preparation method comprises the steps that A, phosphorus pentachloride is dissolved in a solvent, in the presence of an acidamide reagent, cis-form methoxyiminofurylacetic acid amonium salt is added, and through a reaction, a cis-form methoxy-imino furan acetyl chloride solution is obtained; B, a solvent is added to the cis-form methoxy-imino furan acetyl chloride solution, then strong acid or strong base is added, stirring is conducted, and the cis-form methoxy-imino furan acetyl chloride solution is converted into anti-form methoxy-imino furan acetyl chloride. According to the preparation method of the anti-form cefuroxime derivative, on the basis of original preparation of the anti-form methoxy-imino furan acetyl chloride, an innovative method is provided, by adding a proper quantity of solvent, in the presence of the strong acid or strong base, cis-trans isomerism conversion is conducted, andaccordingly the high-purity anti-form cefuroxime derivative can be efficiently prepared through a synthesis method.

The invention discloses a preparation method of descarbamoyl cefuroxime, which comprises the following steps: performing condensation reaction on 3-deacetyl-7-aminocephalosporanic acid used as a parent nucleus for synthesis of the descarbamoyl cefuroxime and a 2-methoxyimino-2-furanammoniumacetate acyl chloride solution, standing, crystallizing with ethanol/hydrochloric acid, washing, performing vacuum filtration, and drying to obtain the product descarbamoyl cefuroxime. The method uses 3-deacetyl-7-aminocephalosporanic acid as the raw material, uses ethanol for crystallization, shortens the production cycle, and is safe and low in toxicity; and meanwhile, the method is mild in reaction conditions and convenient to realize industrial production.

The invention belongs to the technical field of crystallization of pharmaceutical intermediates, and discloses a preparation process for cefuroxime acid crystallization. The process provided by the invention comprises the following concrete steps: adding a cefuroxime acid material liquid prepared in an upstream process into a crystallizer, adding a proper amount of a crystal modifier, adjusting a certain temperature and stirring rate; dropwise adding hydrochloric acid and adjusting the pH value of the mixed solution to a certain value, adding a proper amount of seed crystals, and allowing crystals to grow; adjusting the stirring rate and the hydrochloric acid dropwise adding rate, continuously dropwise adding the hydrochloric acid, and after the completion of dropwise adding, allowing the crystals to grow again; and carrying out filtering, washing and vacuum drying so as to obtain a cefuroxime acid crystallization product. The cefuroxime acid crystal obtained by using the crystallization process provided by the invention has high purity, complete crystal habits and proper particle sizes and particle-size distribution, solves common problems like small product particle size, large crystal slurry viscosity, difficult filtration and drying in the production process of cefuroxime acid in the prior art, shortens the production cycle of products, and reduces production cost.

The present invention generally relates to methods for treating tuberculosis in a subject comprising administering to the subject an antibiotic in conjunction with clavulanic acid or salt thereof. The antibiotic can be carbapenem (e.g., meropenem or imipenem) or cefuroxime. The present invention also relates to related pharmaceutical compositions and methods for manufacturing said pharmaceutical compositions.

The invention discloses a pehanorm salt or hydrate with chemical formula as picture (1) and drug composition and application to treat bacterial infection, which comprises the following parts: cefuroxime oxtatromethane, cepham qusong tromethane, cepham thiotepa tromethane, cefoperazone tromethane, cephalothin tromethane, cefotaxime tromethane, cefolading tromethane, cefonixin tromethane, cefameizin tromethane, cefadizine tromethane, cefuroxime tromethane, cefazolin tromethane, cefapamine tromethane, cefazoline tromethane, cefaadid tromethane, cefaoxofluoride tromethane, cefaminol tromethane and their hydrate.

The present invention relates to safety delivery systems for intracameral administration of an appropriate dose of cefuroxime subsequent to cataract and other eye surgery. A preferred embodiment of an cefuroxime safety delivery system according to the invention comprises (a) a perforable sterile vial sterile-filled with a measured amount of cefuroxime, (b) a reconstitution syringe with a male luer fitting sterile-filled with 0.1 ml of isotonic salt solution per mg cefuroxime in the perforable vial and a vial adapter with a female luer fitting or one or more needles with female luer fitting, and (c) one or more sterilized delivery syringes with male luer fitting, each delivery syringe being capable of holding at least 0.1 ml of ejectable liquid and containing a marking indicating a fill volume of 0.1 ml of ejectable liquid.

The invention relates to a composition of amino-cephalosporanic acid and arginine, which is characterized in that amino-cephalosporanic acid in the composition comprises cefazolin acid, cefuroxime acid, cefamandole nanfate nitrosate, cefonicid acid and cefotetan acid, and one of the above amino-cephalosporanic acids is combined with arginine to obtain the composition. The invention comprises the following steps: in gnotobasis, scaling asepsis arginine and above amino-cephalosporanic acid which have suitable granularity and specific gravity according to ratio of recipe to serve as asepsis bulkdrugs; pouring the drugs into a mixer to operate according to the standard powder mixing operating instruction; after evenly mixed, discharging and slit charging. The composition of the invention solves the problems that sodium salt agent widely applied in cephems drugs specifically has poor crystal form, solution color is easily out of limits, no bacteria exist or pyrogen is not qualified, wateris hard to control, stability is poor and the like. The invention is predicted to have important clinic application value.

The invention belongs to the technical field of a drug intermediate crystal, and particularly relates to a preparation method of 3-deaminized formoxyl-cefuroxime acid crystal. The raw material is 3- deaminized formoxyl-cefuroxime feed liquid prepared in an upstream synthesis process. The specific process includes steps of putting raw materials in a crystallizer according to matching ratio, removing methylene dichloride contained in the feed liquid, and maintaining constant temperature in the crystallizer; adjusting pH value by 10% of diluted hydrochloric acid by mass, and performing isoelectric point crystallization; before producing the crystal, adding the treated 3- deaminized formoxyl-cefuroxime crystal seed; after cultivating the crystal, adjusting pH value to the final point; performing secondary crystal cultivation, filtering, washing and drying, and obtaining a spherical 3-deaminized formoxyl-cefuroxime acid crystal product. The preparation process provided by the invention can effectively shorten the crystal time and avoid problems of too small product granularity and too wide granularity distribution in the production of the 3-deaminized formoxyl-cefuroxime acid; furthermore, the filtering and drying performances are improved, and the production capacity of the production line is promoted.

The invention relates to a cefuroxime lysine compound. The cefuroxime lysine compound contains 98-99.99 wt% of cefuroxime lysine, 0.01-2 wt% of descarbamoyloxy cefuroxime, wherein the molecular formula of the descarbamoyloxy cefuroxime is disclosed as Formula I. The cefuroxime lysine provided by the invention has higher stability than the cefuroxime lysine in the prior art, and lower impurity content and polymer content than the cefuroxime lysine in the prior art, and is very suitable for clinical application.

The invention relates to a cefuroxime lysine compound. The invention is characterized in that the cefuroxime lysine contains 98-99.99 wt% of cefuroxime lysine and 0.01-2 wt% of descarbamoyl cefuroxime, wherein the molecular formula of the descarbamoyl cefuroxime is disclosed as Formula I. The cefuroxime lysine provided by the invention has higher stability than the cefuroxime lysine in the prior art, and lower impurity content and polymer content than the cefuroxime lysine in the prior art, and is very suitable for clinical application.

The present invention discloses salvianolic acid A and a novel use of pharmaceutical composition comprising salvianolic acid A. The invention is characterized by the application of salvianolic acid A in preparing the medicament for treating skin injury, and the application of pharmaceutical composition composed of salvianolic acid A, snow grass, pinellia tuber, phellodendron amurense, cefuroxime, cefalexin, ceftriaxone sodium, etc. in preparing the medicament for treating skin injury. The pharmaceutical and clinical researches show that the salvianolic acid A and pharmaceutical composition comprising salvianolic acid A have excellent treating function for skin injury.

The present invention provides amidases, polynucleotides encoding the amidases, methods of making and using these polynucleotides and polypeptides. In one aspect, the invention provides enzymes having secondary amidase activity, e.g., having activity in the hydrolysis of amides, including enzymes having peptidase, protease and/or hydantoinase activity. In alternative aspects, the enzymes of the invention can be used to used to increase flavor in food (e.g., enzyme ripened cheese), promote bacterial and fungal killing, modify and de-protect fine chemical intermediates, synthesize peptide bonds, carry out chiral resolutions, hydrolyze Cephalosporin C. The enzymes of the invention can be used to generate 7-aminocephalosporanic acid (7-ACA) and semi-synthetic cephalosporin antibiotics, including caphalothin, cephaloridine and cefuroxime. The enzymes of the invention can be used as antimicrobial agents, e.g., as cell wall hydrolytic agents. The invention also provides a fluorescent amidase substrate comprising 7-(epsilon-D-2-aminoadipoyladipoylamido)-4-methylcoumarin.